Gemcitabine with cyclosporine or with tacrolimus exerts a synergistic effect and induces tolerance in the rat

Transplantation

Volumn 76, Issue 7, 2003, Pages 1046-1052

  Jeske, Hans Christian ^a   Oberladstätter, Jürgen ^a   Schneeberger, Stefan ^a   Hittmair, Anton ^a   Klima, Günther ^a   Obrist, Peter ^a   Öllinger, Robert ^a   Roberts, Kurt ^a   Schubert, Heinrich ^a   Steurer, Wolfgang ^a   Margreiter, Raimund ^a  

^a UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; GEMCITABINE; IMMUNOSUPPRESSIVE AGENT; TACROLIMUS;

ALLOGRAFT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; IMMUNOLOGICAL TOLERANCE; INOCULATION; LOW DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; RAT; SKIN GRAFT;

ACUTE DISEASE; ANIMALS; CYCLOSPORINE; DEOXYCYTIDINE; DRUG SYNERGISM; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; IMMUNOSUPPRESSIVE AGENTS; ISOANTIGENS; MALE; RATS; RATS, INBRED LEW; TACROLIMUS; TISSUE DONORS; TRANSPLANTATION TOLERANCE;

EID: 10744221432     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000090544.17227.57     Document Type: Article

References (31)

1. Margreiter R, Fischer M, Roberts K, et al. Gemcitabine - a novel immunosuppressive agent - prevents rejection in a rat cardiac transplantation model. Transplantation 1999; 68: 1051-1053.
2. Yamaguchi Y, Halperin EC, Harland RC, et al. A synergistic effect of total lymphoid irradiation, cyclosporine, and splenectomy in a hamster-to-rat hepatic xenograft model. Transplant Proc 1989; 21: 3356.
3. Smith KA. Interleukin 2: inception, impact, and implications. Science 1988; 240: 1169.
4. Smid K, Van Moorsel CJ, Norhuis P, et al. Interference of gemcitabine triphosphate with measurements of deoxynucleotides using an optimized DNA polymerase elongation assay. Int J Oncol 2001; 19: 157-162.
5. Payr E. Beiträge zur Technik der Blutgefäß- und Nervennaht nebst Mitteilungen über die Verwendung resorbierbaren Metalls in der Chirurgie. Arch Klein Chir 1900; 62: 67.
6. Heron I. A technique for accessory cervical heart transplantation in rabbits and rats. Acta Pathol Microbiol Scand 1971; 79: 366.
7. Kubai L, Auerbach R. Regional differences in the growth of skin transplants. Transplantation 1980; 30: 128.
8. Rosenberg AS, Singer A. Cellular basis of skin allograft rejection: an in vivo model of immune-mediated tissue destruction. Ann Rev Immunol 1992; 10: 333-358.
9. Berenbaum MC. Synergy, additivism and antagonism in immunosuppression: a critical review. Clin Exp Immunol 1977; 28: 1-18.
10. Billingham ME, Cary NR, Hammond ME, et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group. The International Society for Heart Transplantation. J Heart Transplant 1990; 9: 587-593.
11. Ozols RF, O'Dwyer PJ, Hamilton TC. Clinical reversal of drug resistance in ovarian cancer. Gynecol Oncol 1993; 51: 90-96.
12. Yamamoto M, Baba H, Kusumoto T, et al. Cyclosporine A and FK506 reverse anthracycline resistance by altering the cell cycle. Anticancer Drugs 1995; 6: 570-577.
13. Lyubimov E, Lan LB, Pashinsky I, et al. Effect of modulators of the multidrug resistance pump on the distribution of vinblastine in tissues of the mouse. Anticancer Drugs 1996; 7: 60-69.
14. Lindholm A, Welsh M, Rutzky L, et al. The adverse impact of high cyclosporine clearance rates on the incidences of acute rejection and graft loss. Transplantation 1993; 55: 985-993.
15. Chau I, Watkins D, Cunningham D. Gemcitabine and its combinations in the treatment of malignant lymphoma. Clin Lymphoma 2002; 3: 97-104.
16. Heinemann H, Schulz L, Issels R, et al. Gemcitabine: a modulator of intracellular nucleotide and deoxynucleotide metabolism. Seminar Oncol 1995; 22(Suppl 11): 11-18.
17. Plunkett W, Huang P, Gandhi V. Preclinical characteristics of gemcitabine. Anti-Cancer Drugs 1995; 6: 7-13.
18. Deleted in proofs.
19. Stadler WM, Kuzel T, Roth B, et al. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol 1997; 15: 3394-3398.
20. Moore MJ, Tannock IF, Ernst DS, et al. Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol 1997; 15: 3441-3445.
21. Lund B, Hansen OP, Theilade K, et al. Phase II study of gemcitabine (2′,2′-difluodesoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst 1994; 86: 1530-1533.
22. Blackstein M, Vogel CL. Phase II study of gemcitabine in patients with metastatic breast cancer. Proc Am Soc Clin Oncol 1996; 15: 135.
23. Dresske B, Zavazava N, Huang DS, et al. WOFIE augments the immunosuppressive potency of FK-506: window of opportunity for immunological engagement. Transpl Immunol 1998; 6: 243-249.
24. Jung F, Wilker S, Maas E, et al. Gemcitabine in models of acute and accelerated rejection. Transplant Proc 2002; 34: 1420-1421.
25. 2) levels. Invest New Drugs 1997; 15: 115-121.
26. Mottram PL, Raisanen-Sokolowski A, Glysing-Jensen T, et al. Cardiac allografts from IL-4 knockout recipients: assessment of transplant arteriosclerosis and peripheral tolerance. J Immunol 1998; 161: 602-609.
27. Mottram PL, Raisanen-Sokolowski A, Glysing-Jensen T, et al. Redefining peripheral tolerance in the BALB/c to CBA mouse cardiac allograft model: vascular and cytokine analysis after transient CD4 T cell depletion. Transplantation 1998; 66: 1510-1518.
28. Orloff MS, DeMara EM, Coppage ML, et al. Prevention of chronic rejection and graft arteriosclerosis by tolerance induction. Transplantation 1995; 59: 282-288.
29. Akyurek LM, Johnsson C, Lange D, et al. Tolerance induction ameliorates allograft vasculopathy in rat aortic transplants: influence of Fas-mediated apoptosis. J Clin Invest 1998; 101: 2889-2899.
30. Starzl TE, Murase N, Abu-Elmagd K, et al. Tolerogenic immunosuppression for organ transplantation. Lancet 2003; 361(9368): 1502-1510.
31. Day JD, Rayburn BK, Gaudin PB, et al. Cardiac allograft vasculopathy: the central pathogenetic role of ischemia-induced endothelial cell injury. J Heart Lung Transplant 1995; 14: 142-149.